Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 11/2018

10.08.2018 | Retinal Disorders

Incidence and risk factors for neovascular age-related macular degeneration in the fellow eye

verfasst von: Toke Bek, Sidsel Ehlers Klug

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The epidemiology, risk factors, and the effect of anti-VEGF treatment on neovascular age-related macular degeneration (nAMD) have primarily been studied in the first eye developing the disease. The understanding of pathophysiology and planning of follow-up examinations can be improved by knowledge of incidence and risk factors for development of the disease in the fellow eye.

Methods

In a prospective observational cohort study, epidemiological and clinical risk factors for the development of nAMD in the fellow eye among 2516 patients consecutively diagnosed with the disease from a population of 0.9 million citizens during a period of more than 10 years were studied.

Results

nAMD had been diagnosed in the fellow eye of 541 (21.5%) of the patients. The incidence of fellow-eye involvement increased from approximately 5% in patients initially presenting with bilateral disease to approximately 28% more than 6 years after the diagnosis in the first eye. Visual acuity (VA) was higher and central retinal thickness (CRT) was lower in fellow eyes with nAMD diagnosed later than the first eye. Male gender, increasing leakage area, and peripapillary location of the subretinal neovascular membrane in the first eye reduced the risk of developing disease in the fellow eye.

Conclusions

The planning of follow-up examinations of patients diagnosed with nAMD in one eye should consider that the risk of fellow-eye involvement is higher within the first 6 years, in women, and when the leakage area in the first eye is small and not located peripapillary.
Literatur
1.
Zurück zum Zitat Waldstein SM, Simader C, Starurenghi G et al (2016) Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology 123(7):1521–1529CrossRef Waldstein SM, Simader C, Starurenghi G et al (2016) Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology 123(7):1521–1529CrossRef
2.
Zurück zum Zitat Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116(1):57–65CrossRef Brown DM, Michels M, Kaiser PK et al (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116(1):57–65CrossRef
3.
Zurück zum Zitat Abraham P, Yue H, Wilson L (2010) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150(3):315–324CrossRef Abraham P, Yue H, Wilson L (2010) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150(3):315–324CrossRef
4.
Zurück zum Zitat Heier JS, Brown DM, Chong V et al (2012) Intravitral aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537–2548CrossRef Heier JS, Brown DM, Chong V et al (2012) Intravitral aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119(12):2537–2548CrossRef
5.
Zurück zum Zitat Ho AC, Busbee BG, Regillo CD et al (2014) Twenty-four month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 121(11):2181–2192CrossRef Ho AC, Busbee BG, Regillo CD et al (2014) Twenty-four month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 121(11):2181–2192CrossRef
6.
Zurück zum Zitat Maguire MG, Daniel E, Shah AR et al (2013) Comparison of age-related macular degeneration treatments trials (CATT research group). Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120(10):2035–2041CrossRef Maguire MG, Daniel E, Shah AR et al (2013) Comparison of age-related macular degeneration treatments trials (CATT research group). Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120(10):2035–2041CrossRef
7.
Zurück zum Zitat Jonas JB, Tao Y, Rensch F (2011) Bilateral intravitreal bevacizumab injection for exudative age-related macular degeneration: effect of baseline visual acuity. J Ocul Pharmacol Ther 27(4):401–405CrossRef Jonas JB, Tao Y, Rensch F (2011) Bilateral intravitreal bevacizumab injection for exudative age-related macular degeneration: effect of baseline visual acuity. J Ocul Pharmacol Ther 27(4):401–405CrossRef
8.
Zurück zum Zitat Mann SS, Rutishauser-Arnold Y, Peto T et al (2011) The symmetry of phenotype between eyes of patients with early and late bilateral age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 249(2):209–214CrossRef Mann SS, Rutishauser-Arnold Y, Peto T et al (2011) The symmetry of phenotype between eyes of patients with early and late bilateral age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 249(2):209–214CrossRef
9.
Zurück zum Zitat Gamulescu MA, Helbig H (2010) Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration. J Ocul Pharmacol 26(2):213–216CrossRef Gamulescu MA, Helbig H (2010) Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration. J Ocul Pharmacol 26(2):213–216CrossRef
10.
Zurück zum Zitat Bek T, Klug SE (2018) Age, gender and type of medication predict the effect of anti-VEGF treatment on central retinal thickness in wet age-related macular degeneration. Int Ophthalmol 12:473–479 Bek T, Klug SE (2018) Age, gender and type of medication predict the effect of anti-VEGF treatment on central retinal thickness in wet age-related macular degeneration. Int Ophthalmol 12:473–479
11.
Zurück zum Zitat Ibrahim MA, Sepah YJ, Symons RCA et al (2012) Spectra- and time-domain optical coherence tomography measurements of macular thickness in normal eyes and in eyes with diabetic macular edema. Eye 26:454–462CrossRef Ibrahim MA, Sepah YJ, Symons RCA et al (2012) Spectra- and time-domain optical coherence tomography measurements of macular thickness in normal eyes and in eyes with diabetic macular edema. Eye 26:454–462CrossRef
12.
Zurück zum Zitat Solomon SD, Jefferys JL, Hawkins BS, Bressler NM, Bressler SB, Submacular Surgery Trials Research Group (2009) Risk factors for second eye progression to advanced age-related macular degeneration: SST report no. 21. Submacular Surgery Trials Research Group. Retina 29(8):1080–1090CrossRef Solomon SD, Jefferys JL, Hawkins BS, Bressler NM, Bressler SB, Submacular Surgery Trials Research Group (2009) Risk factors for second eye progression to advanced age-related macular degeneration: SST report no. 21. Submacular Surgery Trials Research Group. Retina 29(8):1080–1090CrossRef
13.
Zurück zum Zitat Chevreaud O, Semoun O, Blanco-Garavito R, Kamami-Levy C, Merle B, Jung C, Querques G, Souied EH (2016) Visual acuity at presentation in the second eye versus first eye in patients with exudative age-related macular degeneration. Eur J Ophthalmol 26(1):44–47CrossRef Chevreaud O, Semoun O, Blanco-Garavito R, Kamami-Levy C, Merle B, Jung C, Querques G, Souied EH (2016) Visual acuity at presentation in the second eye versus first eye in patients with exudative age-related macular degeneration. Eur J Ophthalmol 26(1):44–47CrossRef
14.
Zurück zum Zitat Bhisitkul RB, Desai SJ, Boyer DS, Sadda SR, Zhang K (2016) Fellow eye comparisons for 7-year outcomes in ranibizumab-treated AMD subjects from ANCOR, MARINA, and HORIZON (SEVEN-UP study). Ophthalmology 123(6):1269–1272CrossRef Bhisitkul RB, Desai SJ, Boyer DS, Sadda SR, Zhang K (2016) Fellow eye comparisons for 7-year outcomes in ranibizumab-treated AMD subjects from ANCOR, MARINA, and HORIZON (SEVEN-UP study). Ophthalmology 123(6):1269–1272CrossRef
15.
Zurück zum Zitat Chew EY, Clemons TE, SanGiovanni J et al (2013) Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the age-related eye disease study 2 (AREDS2) randomized clinical tria. JAMA 309(19):2005–2015CrossRef Chew EY, Clemons TE, SanGiovanni J et al (2013) Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the age-related eye disease study 2 (AREDS2) randomized clinical tria. JAMA 309(19):2005–2015CrossRef
16.
Zurück zum Zitat Yanagi Y, Mohla A, Lee WK et al (2017) Prevalence and risk factors for nonexudative neovascularization in the fellow eyes of patients with unilateral age-related macular degeneration and polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci 58(9):3488–3495CrossRef Yanagi Y, Mohla A, Lee WK et al (2017) Prevalence and risk factors for nonexudative neovascularization in the fellow eyes of patients with unilateral age-related macular degeneration and polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci 58(9):3488–3495CrossRef
17.
Zurück zum Zitat Tamura H, Tsujikawa A, Yamashiro K et al (2012) Association of ARMS2 genotype with bilateral involvement of exudative age-related macular degeneration. Am J Ophthalmol 154(3):542–548CrossRef Tamura H, Tsujikawa A, Yamashiro K et al (2012) Association of ARMS2 genotype with bilateral involvement of exudative age-related macular degeneration. Am J Ophthalmol 154(3):542–548CrossRef
18.
Zurück zum Zitat Schick T, Altay L, Viehweger E et al (2016) Genetics of unilateral and bilateral age-related macular degeneration severity stages. PLoS One 11(6):e0156778CrossRef Schick T, Altay L, Viehweger E et al (2016) Genetics of unilateral and bilateral age-related macular degeneration severity stages. PLoS One 11(6):e0156778CrossRef
19.
Zurück zum Zitat Javitt JC, Zhou Z, Maguire MG, Fine SL, Willke RJ (2003) Incidence of exudative age-related macular degeneration among elderly Americans. Ophthalmology 110(8):1534–1539CrossRef Javitt JC, Zhou Z, Maguire MG, Fine SL, Willke RJ (2003) Incidence of exudative age-related macular degeneration among elderly Americans. Ophthalmology 110(8):1534–1539CrossRef
20.
Zurück zum Zitat Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG (2012) Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 119(3):571–580CrossRef Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG (2012) Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 119(3):571–580CrossRef
21.
Zurück zum Zitat Chakravarthy U, Wong TY, Fletcher A et al (2010) Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol 10:31CrossRef Chakravarthy U, Wong TY, Fletcher A et al (2010) Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol 10:31CrossRef
22.
Zurück zum Zitat Kuroda Y, Yamashiro K, Miyake M et al (2015) Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology 122(11):2303–2310CrossRef Kuroda Y, Yamashiro K, Miyake M et al (2015) Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology 122(11):2303–2310CrossRef
23.
Zurück zum Zitat Coleman DJ, Silverman RH, Rondeau MJ, Lloyd HO, Khanifar AA, Chan RV (2013) Age-related macular degeneration: choroidal ischaemia? Br J Ophthalmol 97(8):1020–1023CrossRef Coleman DJ, Silverman RH, Rondeau MJ, Lloyd HO, Khanifar AA, Chan RV (2013) Age-related macular degeneration: choroidal ischaemia? Br J Ophthalmol 97(8):1020–1023CrossRef
25.
Zurück zum Zitat Govetto A, Sarraf D, Figueroa MS et al (2017) Choroidal thickness in non-neovascular versus neovascular age-related macular degeneraiton: a fellow eye comparative study. Br J Ophthalmol 101(6):764–769CrossRef Govetto A, Sarraf D, Figueroa MS et al (2017) Choroidal thickness in non-neovascular versus neovascular age-related macular degeneraiton: a fellow eye comparative study. Br J Ophthalmol 101(6):764–769CrossRef
26.
Zurück zum Zitat Boltz A, Luksch A, Wimpissinger B et al (2010) Choroidal blood flow and progression of age-related macular degeneration in the fellow eye in patients with unilateral choroidal neovascularization. Invest Ophthalmol Vis Sci 51(8):4220–4225CrossRef Boltz A, Luksch A, Wimpissinger B et al (2010) Choroidal blood flow and progression of age-related macular degeneration in the fellow eye in patients with unilateral choroidal neovascularization. Invest Ophthalmol Vis Sci 51(8):4220–4225CrossRef
27.
Zurück zum Zitat Bek T, Jørgensen CM (2016) The systemic blood pressure and oxygen saturation in retinal arterioles predict the effect of intravitreal anti-VEGF treatment on diabetic maculopathy. Invest Ophthalmol Vis Sci 57(13):5429–5434CrossRef Bek T, Jørgensen CM (2016) The systemic blood pressure and oxygen saturation in retinal arterioles predict the effect of intravitreal anti-VEGF treatment on diabetic maculopathy. Invest Ophthalmol Vis Sci 57(13):5429–5434CrossRef
28.
Zurück zum Zitat Bressler SB, Ayala AR, Bressler NM et al (2016) Diabetic Retinopathy Clinical Research Network. Persistent macular thickening after Ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol 134(3):278–285CrossRef Bressler SB, Ayala AR, Bressler NM et al (2016) Diabetic Retinopathy Clinical Research Network. Persistent macular thickening after Ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol 134(3):278–285CrossRef
Metadaten
Titel
Incidence and risk factors for neovascular age-related macular degeneration in the fellow eye
verfasst von
Toke Bek
Sidsel Ehlers Klug
Publikationsdatum
10.08.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 11/2018
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-018-4100-z

Weitere Artikel der Ausgabe 11/2018

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2018 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.